Initially approved by the FDA in 2017, durvalumab continues to be a valuable therapeutic option in the field of oncology, providing a targeted approach against PD-L1 to enhance the body’s immune response against cancer cells [14,36,46,47,48,56,57,58,59]. This evidence concerns the gene CD274 and cancer.